Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Caution evidenceCoverage 2/5 core metricsLatest reported free cash flow was -$6M.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Free cash flow was negative
Latest reported free cash flow was -$6M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2023-12-31.
- 3 filing risk checks flagged
Flagged areas: Solvency & liquidity.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Solvency & liquidity
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-11-22
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
Not available for SHPH: no dimensional revenue or operating-income facts for this filer in the ingested DERA files (segment, product/service, geography axes). Missing is not zero - a filer that reports one segment simply has no split to show.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 4,026 US-listed filers · 781 in Materials| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Return on equity net income ÷ stockholders' equity (positive equity only) | -519.9% | 2ndof 3,488 bottom third | 4thof 684 bottom third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -34.5% | 94thof 3,803 top third | 90thof 742 top third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | 882.8% | 1stof 3,262 bottom third | 1stof 652 bottom third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 7 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | fiscal year 2022-12-31 | 10,351,046 shares 10-K 2024-03-21 | 1,337,742 shares 10-K/A 2024-09-04 | -87.1% | first · latest |
| Basic shares WeightedAverageNumberOfSharesOutstandingBasic | fiscal year 2022-12-31 | 10,351,046 shares 10-K 2023-03-15 | 1,337,742 shares 10-K/A 2024-09-04 | -87.1% | first · latest · 3 filings carry it |
| Net income NetIncomeLoss | fiscal year 2022-12-31 | -$3.03M 10-K 2023-03-15 | -$5M 10-K/A 2024-09-04 | -65.0% | first · latest · 3 filings carry it |
| Stock-based compensation ShareBasedCompensation | fiscal year 2022-12-31 | $404K 10-K 2023-03-15 | $238K 10-K/A 2024-09-04 | -41.2% | first · latest · 3 filings carry it |
| Stockholders' equity StockholdersEquity | balance at 2021-12-31 | -$1.63M 10-Q 2022-11-14 | -$1.76M 10-K/A 2024-09-04 | -8.4% | first · latest · 7 filings carry it |
| Operating income OperatingIncomeLoss | fiscal year 2022-12-31 | -$2.55M 10-K 2023-03-15 | -$2.34M 10-K/A 2024-09-04 | +8.2% | first · latest · 3 filings carry it |
| Operating cash flow NetCashProvidedByUsedInOperatingActivities | fiscal year 2022-12-31 | -$2.71M 10-K 2023-03-15 | -$2.67M 10-K/A 2024-09-04 | +1.6% | first · latest · 3 filings carry it |
19 share-count periods re-presented for a stock split (1-for-10, 1-for-25) are listed apart from restatements and not counted above.
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding; share counts re-presented by an integer split ratio are listed as split adjustments, not restatements. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
debt, leases, revenue, segments, contingencies, taxes and more · the filer's own wordsBusiness combinations · 8,215 characters as filed
Note 7 United Dogecoin Merger Agreement On April 30, 2026, the Company entered into an Agreement and Plan of Merger (the Merger Agreement) with Shuttle Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company organized for the purpose of effecting the merger, and United Dogecoin. Upon the closing of the merger on May 6, 2026, Shuttle Merger Sub, Inc. merged with and into United Dogecoin, with United Dogecoin surviving the Merger. As a result of the Merger, United Dogecoin became wholly-owned by the Company. Merger Consideration In connection with the Merger Agreement, the Company issued 8,403 shares of newly designated Series B-1 Convertible Preferred Stock, par value $ 0.00001 per share, to the shareholders of United Dogecoin, in exchange for 100% of their outstanding equity interests. The Series B-1 Convertible Preferred Stock is convertible into shares of the Companys common stock only following receipt of stockholder approval, subject to the terms of the Series B-1 Convertible Preferred Stock, including applicable conversion limitations and beneficial ownership limitations. Further, the Series B-1 Convertible Preferred Stock is a non-voting security prior to its conversion into the Companys common stock. Subject to receipt of stockholder approval, each share of Series B-1 Convertible Preferred Stock is convertible into 403.3 shares of the Companys common stock, par value $ 0.00001 per share, at an initial conversion price of $ 12.40 per share, …
BusinessCombinationDisclosureTextBlock · excerpt; the full note is in the filing
Commitments and contingencies · 7,923 characters as filed
Note 10 Commitments and Contingencies On November 10, 2021, the Company entered into an engagement agreement (EA) with Boustead designating Boustead as its exclusive financial advisor for corporate finance activities and subsequently, on August 29, 2022, the Company entered into an underwriting agreement with Boustead in conjunction with the Companys IPO. The EA contained an up to three year right of first refusal (ROFR) and the Underwriting Agreement, which overrode conflicting terms in the EA, contained a two year ROFR following the September 2, 2022 closing of the Companys IPO. Further, Boustead also had a ROFR in conjunction with the Companys terminated rights offering, which provided Boustead with a ROFR through February 7, 2025. Following the Companys engagement agreement and underwriting agreement with WestPark Capital dated February 10, 2025 and March 13, 2025, respectively, Boustead asserted it has ROFR rights, demanding termination of WestParks engagement and claiming entitlement to compensation under the Boustead EA. As of the reporting date, there are no conditions indicating a loss has been incurred, nor does the Company believe a loss is probable and reasonably estimable, therefore no accrual for a potential loss has been recorded. On December 16, 2024, the Company entered into a sponsored research agreement (the Sponsored Research Agreement) with the Regents of the University of California, on behalf of its San Francisco campus (the UCSF), pursuant to which UCS …
CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing
Debt · 4,228 characters as filed
Note 5 Convertible Notes and Loan Agreement Revolving Note Agreement On February 27, 2025, the Company entered into a Revolving Loan Agreement with Bowery Consulting Group Inc. (Bowery) (the Lender). Pursuant to and under the terms of the Revolving Loan Agreement, the Company issued a revolving note dated February 28, 2025 in the principal amount of up to $ 2,000,000 (the Revolving Note), which the Company may draw upon at its discretion from time to time through its maturity on February 28, 2026. The Company recognized deferred loan costs of approximately $ 78.0 thousand in relation to the closing of the Revolving Loan Agreement and were amortized to interest expense on a straight-line basis to the maturity of the Revolving Loan Agreement. During the three and six months ended June 30, 2026, the Company recognized $ 0 and $ 12.1 thousand in interest expense related to the amortization of these deferred loan costs, respectively. The Revolving Loan expired on February 28, 2026. 2024 Convertible Bridge Notes During October 2024, the Company completed a senior convertible note offering in two closings, as further described below. On October 14, 2024, the Company issued an aggregate of $ 600,000 (of an up to $ 1.3 million authorized financing) senior secured convertible notes due in October 2025, which accrue interest at 14.5 % interest per year. The notes included a 5 % original issue discount and the Company received $ 570.0 thousand in proceeds. The notes were optionally conve …
DebtDisclosureTextBlock · excerpt; the full note is in the filing
Leases · 3,584 characters as filed
Note 3 Leases Operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments as of the lease commencement date. Operating lease expense is recognized on a straight-line basis over the lease term. The Company currently has a lease agreement which allows for the use of a laboratory facility, entered into on February 16, 2023, with base rent of $ 7,206 per month for a period of 64 months, which increases at the rate of 3 % per year, that commenced June 1, 2023 . The lease included a six-month 50 % rent abatement upon commencement. Additional common area maintenance (CAM) fees are charged monthly and revised annually. In addition to monthly base rent, the Company pays monthly CAM fees, which are being expensed as incurred. An irrevocable letter of credit (LOC) for the security deposit of $ 43,234 and base rent of $ 3,891 , including 50 % abatement, and $ 3,315 of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is the beneficiary of the LOC. The current LOC expired on March 1, 2026. Following the Companys discontinuation of its clinical trial for Ropidoxuridine, the Company committed to a plan to pursue a sublease for its laboratory spa ce. During May 2026, the Company executed a sublease agreement for its laboratory space, with the subtenant taking occupancy on May 15, 2026. The sublease has a stated term through August 30, 2028 and is coterminous with the underlying lease. …
LesseeOperatingLeasesTextBlock · excerpt; the full note is in the filing
New accounting pronouncements · 689 characters as filed
Recently Adopted Accounting Pronouncements In December 2023, the FASB issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires disaggregated information about a reporting entitys effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Companys fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-09, effective December 31, 2025, in these unaudited condensed consolidated financial statements. ASU 2023-09 which only impacted the disclosures and did not otherwise impact the unaudited condensed consolidated financial statements. …
NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing
Segment reporting · 3,917 characters as filed
Note 11 Business Segment Information The Company and its consolidated subsidiaries operate as one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the Company as well as licensing the right to use Molecule.ai to others. The CEO, as our chief operating decision maker (CODM), manages and allocates resources to the operations of the Company on a consolidated basis, considering primarily research and development expenditures, investment in the continued development of the Molecule.ai platform cash burn and net loss. This enables the CEO to assess our overall level of available resources and determine how best to deploy these resources across projects in line with the longer-term Company-wide strategic goals. During the year ended December 31, 2025, the Company appointed an Interim CEO, subsequently appointed as Co-CEO, who assumed the role of CODM. This appointment did not result in any immediate changes to the reporting metrics that the CODM uses to manage and allocate resources to the operations of the Company. Our former CEO continued to chair the Companys Board of Directors and serve in a corporate role as Chief Scientific Officer until his retirement on May 9, 2025. The accounting policies of our reportable segment are the same as those described in the Summary of Significant Accounting Pol …
SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing
Significant accounting policies · 33,807 characters as filed
Note 2 Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial statements and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (SEC). Accordingly, they do not contain all information and notes required by GAAP for annual financial statements. A complete discussion of the Companys significant accounting policies is included in the Companys Annual Report on Form 10-K for the year ended December 31, 2025. In the opinion of the Companys management, the accompanying unaudited condensed consolidated financial statements contain all of the adjustments necessary to present the financial position of the Company as of June 30, 2026 and the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements of the Company have not been audited by the Companys independent registered public accounting firm, except that the year-end consolidated balance sheet was derived from audited financial statements. The results of operations for the six months ended June 30, 2026 are not necessarily indicative of the operating results for the full fiscal year or any future period. Reverse Stock Splits On June 16, 2025, in order to maintain a mini …
SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing
Stockholders' equity · 24,638 characters as filed
Note 8 Stockholders Equity Common Stock During the six months ended June 30, 2026, the Company issued: 4,480 shares of common stock issued for vesting of restricted stock units, 223,880 shares of common stock as part of a public offering, 570,411 shares of common stock issued for exercise of pre-funded warrants, and 32 shares of common stock for rounding of reverse stock split fractional shares During the six months ended June 30, 2025, the Company issued: 1,200 shares of common stock upon conversion of $ 81,818 of principal related to a partial conversion of the Convertible Bridge Notes, 5,364 shares of common stock as part of a public offering, 3,402 shares of common stock for vesting of restricted stock units, 2,193 shares of common stock as part of a private placement, 4 shares of common stock for rounding of reverse stock split fractional shares, and 78,607 shares of common stock for exercise of pre-funded warrants. March 2025 Equity Financing On March 12, 2025, the Company entered into an Underwriting Agreement (the Underwriting Agreement) with WestPark Capital, Inc. (WestPark) as the sole underwriter, related to a public offering (the Offering) of (i) 5,364 shares of common stock of the Company, at a public offering price of $ 75.00 per share and (ii) pre-funded warrants to purchase 71,303 shares of common stock at an exercise price of $ 0.25 per share, at a public offering price of $ 74.75 per Pre-Funded Warrant (the March 2025 Pre-Funded Warrants). The Offering close …
StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing
Subsequent events · 2,341 characters as filed
Note 12 Subsequent Events On August 31, 2026, the Company and United Dogecoin entered into a First Amendment to Merger Agreement (the Amendment). The Amendment amends the definition of the Milestone Event by reducing the number of Mining Rigs (as defined in the Merger Agreement) from 2,000 to 500. No other terms of the Merger Agreement were amended or modified by the Amendment, and only the threshold for satisfying the Milestone Event has been amended and not the maximum number of 2026 Pre-Funded Warrants (or shares of common stock underlying such warrants) that would be issuable or issued as a result of satisfying the Milestone Event . On September 9, 2026, the Company had its Special Meeting of Stockholders (the Special Meeting), at which the Companys stockholders approved (a) the issuance of the Companys shares of Common Stock and 2026 Pre-Funded Warrants in connection with the transactions contemplated by the Merger Agreement and the Second Amendment, including shares issuable upon conversion of shares of Series B-1 Convertible Preferred Stock and upon the exercise of the 2026 Pre-Funded Warrants, (b) the issuance of the Companys shares of Common Stock and 2026 Pre-Funded Warrants in connection with the transactions contemplated by the Securities Purchase Agreement, including shares issuable upon conversion of shares of Series B-2 Preferred Stock, upon exercise of common stock purchase warrants and upon exercise of the 2026 Pre-Funded Warrants, (c) an amendment to the Com …
SubsequentEventsTextBlock · excerpt; the full note is in the filing
Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.